$CELG Recent News Two growth stocks that look ready to

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 10:40 AM

$CELG Recent News

Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Tech ETF QQQ gains on Facebook, other earnings 8:48 a.m. July 25, 2013 - Victor Reklaitis
Celgene profit up 30% as Revlimid sales increase 6:55 a.m. July 25, 2013 - MarketWatch.com
4 things traders should know for the next 24 hours 5:37 p.m. July 24, 2013 - blogs.marketwatch.com
The Next 24: Internet Stocks Jump 3:39 p.m. July 24, 2013 - MarketWatch
Charting a slow-motion rally to record territory 11:06 a.m. July 23, 2013 - Michael Ashbaugh
Charting a slow-motion rally to record territory 10:50 a.m. July 23, 2013 - Michael Ashbaugh
Thursday’s movers: Microsoft rallies on revamp 3:44 p.m. July 11, 2013 - Sue Chang
Celgene's study data may boost cancer drug sales 1:37 p.m. July 11, 2013 - MarketWatch.com
Celgene shares surge on test results from cancer treatment 10:36 a.m. July 11, 2013 - Russ Britt

What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Today - TheStreet.com
How big pharma sells A.D.H.D 5:13 p.m. Dec. 15, 2013 - Seeking Alpha
Ziopharm: Finally A Winner In The War On Cancer? 1:22 p.m. Dec. 15, 2013 - Seeking Alpha
2013 Top Stocks Netflix, Micron May Not Do as Well in 2014 10:55 a.m. Dec. 13, 2013 - TheStreet.com
Celgene, Agios Extend Tie-up - Analyst Blog 11:30 a.m. Dec. 12, 2013 - Zacks.com
3 Large Cap Healthcare Stocks That Belong in Your Portfolio 9:23 a.m. Dec. 12, 2013 - Wall St. Cheat Sheet
Follow The Money 5:23 a.m. Dec. 12, 2013 - Seeking Alpha
Spread the Love With CELG Stock Options 3:20 a.m. Dec. 12, 2013 - InvestorPlace.com
Novartis: 2 Novel Cancer Therapies Show Promising Results 2:13 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene, Agios extend cancer collaboration 2:12 p.m. Dec. 11, 2013 - Seeking Alpha
Celgene And The Chronic Disease Fund: The Next Domino To Fall? 12:08 p.m. Dec. 11, 2013 - Seeking Alpha
Will Biotech Outperform Again in 2014? 10:47 a.m. Dec. 11, 2013 - Barrons.com
Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog 10:41 a.m. Dec. 11, 2013 - Zacks.com
The Best Biotech CEO of 2013 is... 10:01 a.m. Dec. 11, 2013 - TheStreet.com
The One True Sector Bubble: Profits Here When It Crashes Soon 9:17 a.m. Dec. 11, 2013 - benzinga.com
Credit Suisse Offers Top Biotech Stocks to Buy for 2014 8:10 a.m. Dec. 11, 2013 - 247WallSt.com
Did The Government Shutdown Help The Economy? 6:39 p.m. Dec. 10, 2013 - Seeking Alpha
Celgene Rises on Positive Revlimid Data - Analyst Blog 5:20 p.m. Dec. 10, 2013 - Zacks.com
Jim Cramer's 6 Stocks in 60 Seconds: FDX PVH TWTR BURL CELG PF (Update 1) 5:10 p.m. Dec. 10, 2013 - TheStreet.com
Newly Transformed Nuvilex To Enjoy Strong 2014 11:33 a.m. Dec. 10, 2013 - Seeking Alpha

Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Alliqua Announces Transaction with Celgene 7:30 a.m. Nov. 19, 2013 - BusinessWire
Acquisitions, Quarterly Reports, and Stock Price Movements - Research Report on Santarus, Celgene, Pharmacyclics, Quest Diagnostics, and Stryker 8:00 a.m. Nov. 13, 2013 - PR Newswire
Initial Phase III Results of the FIRST(R) Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting 9:02 a.m. Nov. 7, 2013 - BusinessWire
Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna, and Boston Scientific 8:00 a.m. Nov. 6, 2013 - PR Newswire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 4:03 p.m. Oct. 31, 2013 - PR Newswire
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 9:00 a.m. Oct. 30, 2013 - PR Newswire
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 30, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shell Seals ARC Acquisition, $16.5B Bet on Future

Shell’s Strategic Play: Snagging ARC When it comes to Shell, they don't dawdle with peanuts. Snagging ARC Resources Ltd., a Canadian energy firm rooted squarely in British Columbia and Alberta, speaks volumes about their appetite for growth. They’re shelling out approximately US$16.5 billion to pull this deal off the ground. This isn't just some casual sector play; it...

HIMS Faces Class Action: Investors Eye Leadership

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

VT Markets Appoints Maxwell for Global Expansion

Maxwell Joins VT Markets Amid Strategic Shift Forget the usual humdrum of C-suite comings and goings; this one's packed with punch. VT Markets is setting the stage for a serious leap forward by naming Ross Maxwell their new Chief Strategy Officer. This isn't just another desk job—it's a pivotal role meant to integrate cutting-edge technology with the ever-evolving...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Capricor Faces Lawsuit: Investors Should Take Note

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Joseph Spine Opens New Regenerative Therapy Center

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Check Point Shareholders Back 2026 AGM Proposals

Shareholder Endorsement Solidifies Check Point's Strategy Today, Check Point Software Technologies had a bit of a celebratory mood. Their stakeholders, it seems, aren't just riding the wave; they're all in. You could almost hear the cheers from Redwood City when those shareholder voting results flashed across the board. Some 81.2 million shares—encompassing about 79.52%...

TCOM Secures $600M Deal to Boost NATO's Defense

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

ITP Media's Bold Move: Ready for Asian Market Surge

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Ecobat's Strategic Shift: Exiting Lithium for Lead

You ever get that sense of déjà vu when another company decides to jump ship from a supposedly hot market? Well, that's where Ecobat's at, folks. This global player in battery recycling just waved goodbye to its lithium recycling biz, closing the deal on its Arizona operations. Previously, they ditched similar holdings in the UK and Germany. Now, they're all-in on their...